OncoMatch/Clinical Trials/NCT06815666

BAL Fluid Biomarkers in Sarcoma

Is NCT06815666 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for soft tissue sarcoma (sts).

Phase 2RecruitingUniversity Health Network, TorontoNCT06815666Data as of May 2026

This is a single-centre, Phase II, prospective study designed to assess BALF and TA-derived biomarkers in relation to metastatic burden in STS patients. BALF and TA samples will be collected during routine bronchoscopy performed as part of standard care at Toronto General Hospital (TGH). Additionally, tissue samples of lung metastases and adjacent normal lung will be collected and used to correlate the identified biomarkers.

Check if I qualify

Extracted eligibility criteria

Cancer type

Sarcoma

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify